Role of Bisoprolol and Dapagliflozin in the Management of Cardiometabolic Disorders: A Comprehensive Review

Abstract

Cardiometabolic disorders comprise a spectrum of interrelated conditions such as hypertension, type 2 diabetes mellitus, heart failure, coronary artery disease, obesity, and metabolic syndrome, which collectively contribute to increased global morbidity and mortality. The close association between cardiovascular and metabolic abnormalities necessitates integrated therapeutic strategies that address both components simultaneously. Bisoprolol, a highly selective ?1-adrenergic receptor blocker, is widely used in cardiovascular disorders due to its ability to reduce heart rate, myocardial contractility, and renin release with minimal metabolic adverse effects. Dapagliflozin, a sodium–glucose co-transporter-2 (SGLT2) inhibitor, initially developed as an antidiabetic agent, has demonstrated significant cardiovascular and renal protective benefits independent of glycemic control. This comprehensive review highlights the pharmacological profile, pharmacokinetics, pharmacodynamics, clinical applications, safety, drug interactions, and future perspectives of bisoprolol and dapagliflozin. Emphasis is placed on their complementary mechanisms of action and their combined role in the management of cardiometabolic disorders. The integration of these agents represents a rational and effective approach toward improving cardiovascular outcomes, metabolic control, and overall patient prognosis.

Keywords

Cardiometabolic disorders, Bisoprolol, Dapagliflozin, ?1-Adrenergic blocker, SGLT2 inhibitor, Heart failure, Type 2 diabetes mellitus, Cardiovascular protection ,Renal protection, Combination therapy

Introduction

Dapagliflozin is a newer class of oral antidiabetic drug belonging to the sodium–glucose co-transporter 2 (SGLT2) inhibitors. It exerts its glucose-lowering effect by selectively inhibiting SGLT2 in the proximal renal tubules, thereby preventing glucose reabsorption and promoting urinary glucose excretion.(6,7)This insulin-independent mechanism of action distinguishes dapagliflozin from conventional antidiabetic agents such as sulfonylureas and insulin, significantly reducing the risk of hypoglycemia.[8]

The complementary pharmacological actions of Bisoprolol Fumarate and Dapagliflozin make their combination particularly relevant for patients suffering from both cardiovascular and metabolic disorders. While Bisoprolol primarily modulates cardiac function by reducing sympathetic activity, dapagliflozin improves metabolic control and provides additional cardiovascular protection through hemodynamic and metabolic mechanisms. Therefore, the concurrent use of these drugs represents a rational and effective therapeutic approach in modern cardiometabolic management.[9] With the increasing use of combination therapies, ensuring the quality, safety, and stability of pharmaceutical products has become critically important. Regulatory authorities such as the International Council for Harmonisation (ICH) emphasize the need for comprehensive analytical evaluation of drug substances and drug products. Analytical techniques play a vital role in drug development, quality control, stability testing, and regulatory compliance.[10]

2. DRUG PROFILE OF BISOPROLOL

Chemical Structure: Synthetic β1-selective adrenergic blocker

IUPAC Name: (RS)-1-[4-[(2-isopropoxyethoxy) methyl]phenoxy]-3-(isopropylamino)propa-2-ol

Molecular Formula: C??H??NO?

Molecular Weight : 325.44 g/mol

Physical Properties:

• Appearance: White or almost white crystalline powder
• Odor: Odorless
• Solubility: Freely soluble in water and methanol[11]

Storage: Store below 25°C, protected from moisture, Keep in tightly closed container

Uses: Hypertension, chronic heart failure, angina pectoris, ischemic heart disease [12]

Dosage: Bisoprolol fumarate is administered orally as 5 or 10 mg tablets once daily.

Advantages in Cardiometabolic Disorders:

• High β1-selectivity → safer in diabetic patients
• Minimal effect on lipid & glucose metabolism
• Reduces mortality in heart failure

Adverse Effects: Bradycardia, hypotension, fatigue, dizziness [13,14]

3. DRUG PROFILE OF DAPAGLIFLOZIN

Chemical Structure: SGLT2 inhibitor derived from C-aryl glucoside

IUPAC Name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl) tetrahydro-2H-pyran-3,4,5-triol

Molecular Formula: C??H??ClO?

Molecular Weight: 408.88 g/mol

Physical Properties:

• Appearance: White to off-white crystalline powder
• Solubility: Slightly soluble in water, soluble in organic solvents

Storage: Store at room temperature(20–25°C),Protect from excessive heat and moisture

Uses: Type 2 diabetes mellitus, heart failure, chronic kidney disease

Dosage: Taken once daily in the morning, with or without food 5 or 10 mg tablet.

Advantages in Cardiometabolic Disorders:

• Insulin-independent glucose lowering
• Reduces heart failure hospitalization
• Renal protective effect
• Weight loss and mild BP reduction

Adverse Effects: Genital infections, dehydration, hypotension [15,16]

4. PHARMACOLOGICAL ACTION

Bisoprolol selectively blocks β1-adrenergic receptors, reducing sympathetic stimulation of the heart.Selective B1 blocker drugs have negative inotropic and chronotropic effects; they decrease heart contractions and heart rate. As a net result, bisoprolol reduces the oxygen consumption of myocardial cells. B1 receptors are also present in the juxtaglomerular cells. By blocking these receptors, bisoprolol leads to a decrease in the release of renin; as a result, this decrease in renin blocks the activation of the renin-angiotensin system.[17]

B1 adrenergic receptors are present in cardiac myocyte cells and juxtaglomerular cells. They couple with the G-stimulatory protein receptor (Gs receptor) and become stimulated by either norepinephrine or circulating catecholamine. Activation of B1 receptors in cardiac myocytes leads to positive chronotropic and inotropic effects; therefore, the net result will be increased heart rate, contraction, and the strength of myocyte contraction by activating Gs receptors (by the exchange of GTP to GDP). Eventually, this activity increases intracellular calcium concentration and promotes heart cell contraction. [ 18,19,20 ] Activation of B1 receptors on juxtaglomerular cells leads to activating the renin-angiotensin system. Releasing renin increases the production of angiotensin I, which is eventually converted by an angiotensin-converting enzyme (ACE) to angiotensin II.

Dapagliflozin inhibits SGLT2 in the renal proximal tubules, promoting urinary glucose excretion. Dapagliflozin is a potent, highly selective reversible, orally active competitive sodium glucose co-transporter-2 (SGLT2) inhibitor with potency at nanomolar stage that effect in the maintenance of glycemic control in patients with type 2 diabetes mellitus by reducing renal glucose reabsorption leading to urinary glucose excretion (glycuresis)[21,22,23]

SGLT-2 is selectively expressed in the kidney with no expression detected in more than 70 other tissues including liver, skeletal muscle, adipose tissue, breast, bladder, and brain. SGLT-2 is the predominant transporter that causes the reabsorption of glucose from the glomerular filtrate back into the circulation. This does not affect the insulin secretion but continues to inhibit the reabsorption of filtered glucose.[21] Even by this inhibition, it causes maintenance. of both fasting and post-prandial plasma glucose levels, thus it results in the consumption of fat as an energy source. [24]But Glomerular Filtration Rate (GFR) and blood glucose concentration are the factors on which the amount of glucose removed by the kidney through this mechanism is depended. Thus, in healthy subjects with normal glucose, dapagliflozin has a low propensity to cause hypoglycemia. Dapagliflozin acts independently of insulin secretion and insulin action. Over time, improvement in beta cell function (HOMA-2) has been observed in clinical studies with dapagliflozin.[21]

5. PHARMACODYNAMICS

Bisoprolol decreases heart rate, myocardial contractility, and renin release. Bisoprolol is a β1-adrenoceptor antagonist which has been shown to be devoid of partial agonist or membrane-stabilising activity. Animal studies have shown that bisoprolol is a more potent antagonist of β1-adrenoceptors than atenolol or metoprolol, but the drug appears to be less potent than propranolol and betaxolol in this regard. Bisoprolol possesses a long duration of action, with significant reductions in exercise tachycardia (about 20%) being observed in subjects with stable angina pectoris 24 hours after oral administration of 5 and 10mg. Both systolic and diastolic blood pressures are reduced by bisoprolol (by up to about 20%, respectively, in healthy subjects and in patients with mild to moderate essential hypertension) as well as myocardial oxygen demand (by up to 34%).[25]

Statistically significant increases in serum triglycerides (p<0.05) and reductions in high density lipoprotein (HDL)-cholesterol (bisoprolol, p<0.01; atenolol, p<0.05) were reported in a 3-month comparison of oral bisoprolol 10 and 20 mg/day and atenolol 50 and 100 mg/day in patients with mild to moderate essential hypertension. However, the overall effects of bisoprolol on lipid metabolism are as yet still unclear and further studies in this area are required.[26]

Dapagliflozin reduces plasma glucose levels and improves cardiovascular outcomes through osmotic diuresis and reduced preload.Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin . Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/ day) at a Dapagliflozin dose of 10 mg/day in patients with type 2 diabetes mellitus for 12 weeks. This glucose elimination rate approached the maximum glucose excretion observed at 20 mg/day dose of dapagliflozin. Evidence of sustained glucose excretion was seen in patients with type 2 diabetes mellitus given dapagliflozin 10mg/day for up to 2 years. This urinary glucose excretion with dapagliflozin also results in osmotic diuresis and increases in urinary volume. Urinary volume increases in patients with type 2 diabetes mellitus treated with Dapagliflozin 10 mg were sustained at 12 weeks and amounted to approximately 375 ml/day. The increase in urinary volume was associated with a small and transient increase in urinary sodium excretion that was not associated with changes in serum sodium concentrations.[22]

6. PHARMACOKINETIC

Bisoprolol :- Absorption: Bisporolol is well absorbed, and the bioavailability of bisoprolol is approximately 80%. The time to peak plasma concentration is approximately 2 to 4 hours. Steady-state plasma concentration is achieved in 5 days.[28]

Distribution: Bisoprolol has low lipophilicity; penetration the through the blood-brain barrier is minimal. The volume of distribution of about 3.5 L/kg.[29]

Metabolism: Bisoprolol is primarily metabolized by the CYP3A4 and CYP2D6(minor). First-pass metabolism of bisoprolol is low.[30]

Excretion: Bisoprolol is eliminated by 50% renal excretion (unchanged drug) and 50% by hepatic metabolism to pharmacologically inactive metabolites excreted by the kidneys. Tubular secretion plays an important role in the renal elimination of bisoprolol. Excretion through feces is approximately 2%.[31, 32]

Dapagliflozin:-  Absorption: Following the oral administration of drug. maximum plasma concentration (Cmax) is usually attained within 2 hours under fasting state. The Cmax and AUC values increase dose proportionally with increase in dapagliflozin dose in the therapeutic dose range. 78% of absolute bioavailability is attained by 10mg of dapagliflozin drug administered. Also, with co-administration of high fat meal, it causes decreased in its Cmas by upto 50% andprolongs Tmax by approximately I hour, but does not alter AUC as compared with the fasted state. But they are not clinically meaningful and dapagliflozin can be administered with or without food.

Distribution: It is approximately 91% protein bound. Protein binding is not altered in patients with renal or hepatic impairment.[33]

Metabolism: The metabolism pathway of Dapagliflozinis mainly mediated by UGTIA9; CYP mediated metabolism is a major clearance pathway. in human. Drug is extensively metabolized, primarily to yield dapagliflozin 3-0- glucuronide, which is an inactive metabolite". Dapagliflozin 3-O- glucuronide (BMS 801576). The primary metabolite accounts for 61% of the dapagliflozin dose.[34]

Excretion: Dapagliflozin and related metabolites are primarily eliminated by the renal pathway. Following a single dose 50mg dose of [14]-dapagliflozin, 75% and 21% total radioactivity is excreted in urine and feces, respectively. In urine less than 2% of the dose is excreted as the parent drug. In feces approximately 15% of the drug is excreted as parent drug. The mean plasma terminal half life (11/2) for dapagliflozin is approximately 12.9 hours following a single oral dose.[33]

7. CLINICAL ROLE IN CARDIOMETABOLIC DISORDERS

1. Clinical Role of Bisoprolol

a) Hypertension

• Bisoprolol reduces blood pressure
• Decreasing heart rate and cardiac output
• Inhibiting renin release from kidneys
• Reducing sympathetic nervous system activity

b) Chronic Heart Failure

• Improves left ventricular function
• Reduces hospitalization
• Significantly decreases cardiovascular and all-cause mortality

c) Ischemic Heart Disease

• Preventing angina
• Reducing risk of myocardial infraction

d) Cardiometabolic Advantage

• Minimal effect on glucose metabolism
• Less risk of masking hypoglycemia compared to non-selective β-blockers .This makes it suitable for patients with diabetes and metabolic syndrome.[35,36,38]

2. Clinical Role of Dapagliflozin

a) Type 2 Diabetes Mellitus

• Dapagliflozin lowers blood glucose
• Inhibiting renal glucose reabsorption
• Promoting urinary glucose excretion

b) Heart Failure

• Dapagliflozin has emerged as a landmark therapy for heart failure, irrespective of diabetic status.
• Reduces hospitalization for heart failure
• Improves cardiovascular outcomes
• Reduces preload and afterload through osmotic diuresis

c) Renal Protection

• Dapagliflozin slows progression of chronic kidney disease (CKD) by:
• Reducing intraglomerular pressure
• Improving renal hemodynamics

d) Cardiometabolic Benefits

• Reduces body weight and visceral fat
• Lowers blood pressure
• Improves lipid profile
• Reduces inflammation and oxidative stress[37,39]

8. SAFETY AND TOLERABILITY

Bisoprolol is a highly β1-selective adrenergic blocker with a well-established safety and tolerability profile in patients with cardiometabolic disorders. Clinical studies have shown that bisoprolol is generally well tolerated when initiated at low doses and gradually titrated. Common adverse effects include bradycardia, fatigue, dizziness, hypotension, and cold extremities, which are usually mild to moderate and dose-dependent. Due to its β1-selectivity, bisoprolol has minimal adverse effects on glucose and lipid metabolism, making it safer for patients with diabetes mellitus and metabolic syndrome compared to non-selective β-blockers.[40] Large clinical trials such as CIBIS-II have demonstrated a significant reduction in cardiovascular mortality and hospitalization in heart failure patients without compromising safety. However, caution is advised in patients with bronchial asthma, severe bradycardia, or conduction abnormalities, and abrupt discontinuation should be avoided to prevent rebound cardiovascular effects.[41]

Dapagliflozin, a selective sodium–glucose co-transporter-2 (SGLT2) inhibitor, has demonstrated favorable safety and tolerability in both diabetic and non-diabetic patients with cardiometabolic disorders. It is associated with a low risk of hypoglycemia when used alone, as its glucose-lowering effect is insulin-independent.[42] Common adverse effects include genital mycotic infections, urinary tract infections, polyuria, and mild volume depletion, which are generally manageable and reversible. Clinical outcome trials such as DECLARE-TIMI 58 and DAPA-HF have confirmed that dapagliflozin does not increase cardiovascular risk and significantly reduces hospitalization for heart failure, with added renal protective effects.[43] Although a transient decline in estimated glomerular filtration rate (eGFR) may be observed initially, long-term therapy slows the progression of chronic kidney disease. Rare but serious adverse events such as euglycemic diabetic ketoacidosis and Fournier’s gangrene have been reported, necessitating careful patient selection and monitoring.[44]

9. DRUG INTERACTIONS

Bisoprolol interacts with calcium channel blockers. Abrupt discontinuation of clonidine while taking bisoprolol results in a catecholamine surge and can lead to rebound hypertension. Bisoprolol should be stopped several days before the discontinuation of clonidine.[45] Concomitant use of bisoprolol with calcium channel blockers such as verapamil and diltiazem may worsen the myocardial function and result. in hypotension, bradycardia, and AV block.[46] Strong CYP3A4 induces, like rifampin, increases the clearance of bisoprolol. resulting in a short elimination half-life of bisoprolol.[47] Concomitant administration of cholinesterase inhibitors like donepezil with bisoprolol can increase the risk for bradycardia, falls, and syncope. Concomitant use of bisoprolol with digoxin delays AV conduction and can increase the risk of bradycardia.[48]

There were no clinically meaningful drug-drug interactions observed with several concomitant medications used by T2DM patients, like metformin, sitagliptin, digoxin, simvastatin, and warfarin. No drug-drug interactions were observed with drugs that may affect the metabolic pathway of Dapagliflozin (eg, mefenamic acid and rifampin). Also, they demonstrated that dapagliflozin has little potential either to affect metabolism or to have its metabolism meaningfully affected by co administration of other drugs. The mean exposure to dapagliflozin in subjects with moderate and severe hepatic impairment was 36% and 67% higher, respectively, than that of healthy subjects.[34]

10. FUTURE PERSPECTIVES

Bisoprolol

• Will continue to be a preferred β1-selective beta-blocker in cardiometabolic disorders
• Increasing use in patients with heart failure, hypertension, and diabetes due to metabolic safety
• Future focus on personalized dosing and pharmacogenomic approaches
• Strengthened role in combination therapy with SGLT2 inhibitors, ACE inhibitors, and ARNI
• Potential development of fixed-dose combinations to improve long-term patient adherence. [49]

Dapagliflozin

• Expanding role beyond glycemic control to heart failure and chronic kidney disease
• Increased use in non-diabetic patients with heart failure
• Early initiation to prevent disease progression in high-risk cardiometabolic patients
• Ongoing research on cardio-renal protective and anti-inflammatory mechanisms
• Expected to become a standard component of cardiometabolic therapy[50]

11. CONCLUSION

Cardiometabolic disorders represent a major global health challenge due to the complex interplay between cardiovascular and metabolic abnormalities such as hypertension, type 2 diabetes mellitus, heart failure, and chronic kidney disease. Effective management of these conditions requires therapeutic strategies that provide both cardiovascular and metabolic benefits. Bisoprolol and dapagliflozin have emerged as important pharmacological agents fulfilling these requirements.

Bisoprolol, a highly selective β1-adrenergic blocker, offers significant cardiovascular protection by reducing heart rate, myocardial contractility, and sympathetic overactivity while exerting minimal adverse effects on glucose and lipid metabolism. Its proven efficacy in hypertension, ischemic heart disease, and chronic heart failure makes it particularly suitable for patients with coexisting metabolic disorders. Dapagliflozin, a selective SGLT2 inhibitor, provides insulin-independent glycemic control along with robust cardiovascular and renal protective effects. Its ability to reduce heart failure hospitalization, slow the progression of chronic kidney disease, promote weight loss, and lower blood pressure highlights its expanding role beyond diabetes management.

The complementary mechanisms of action of bisoprolol and dapagliflozin support their combined use in patients with cardiometabolic disorders, offering a holistic and patient-centered therapeutic approach. Clinical evidence strongly supports their safety, tolerability, and long-term benefits in improving cardiovascular outcomes and overall quality of life. With ongoing research and evolving clinical guidelines, the integration of bisoprolol and dapagliflozin is expected to play an increasingly important role in the comprehensive management of cardiometabolic disorders in the future.

REFERENCES

1. Bazroon AA, Alrashidi NF. Bisoprolol. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. — Describes bisoprolol as a selective β1-blocker, its mechanism, and uses in hypertension and heart failure.
2. “Bisoprolol.” Wikipedia — Overview of pharmacology, cardioselective β1-blocker properties, and cardiovascular uses.
3. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol… (cited in PubMed review) — Evidence supporting β1 selectivity and reduced metabolic side effects of bisoprolol-class agents.
4. Khan MS, Butler J, et al. Optimizing Cardiovascular Outcomes With Bisoprolol. — Discusses bisoprolol’s efficacy and safety in cardiovascular disease management.
5. Holman RR, et al. Cardiovascular Safety and Benefits of Dapagliflozin in T2DM. PubMed — Reviews dapagliflozin effects on CV outcomes and heart failure risk in T2DM.
6. Avgerinos KI, et al. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. PubMed — Summarizes large outcomes trials showing dapagliflozin decreases HF hospitalizations and renal risk.
7. “Dapagliflozin.” Wikipedia — Overview of medical uses, CV benefits and kidney protective effects beyond glucose lowering.
8. McMurray JJV, Solomon SD, et al. DAPA-HF Trial. (Often cited in CV outcome literature) — Landmark clinical trial showing CV benefit of dapagliflozin in HF patients with/without diabetes (referenced in MDPI/CDC reviews).
9. Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors. MDPI Pharmaceuticals — Describes dapagliflozin’s mechanisms of natriuresis, reduced blood pressure, and cardioprotective effects independent of glycemic control
10. Cardiovascular Endocrinology & Metabolism (2023) — Provides data on the global prevalence of T2DM, its association with CVD, and combined cardiometabolic risk.
11. Sweetman SC, ed. Martindale: The Complete Drug Reference. 40th ed.London: Pharmaceutical Press; 2020.→ (IUPAC name, molecular formula, physical properties, storage, uses, adverse effects)
12. Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.→ (β1-selectivity, safety in diabetic patients, cardiovascular benefits)
13. Goodman & Gilman.The Pharmacological Basis of Therapeutics. 13th ed.New York: McGraw-Hill; 2018. → (Pharmacological action, heart failure mortality reduction)
14. Micromedex® Solutions. Bisoprolol Drug Monograph.IBM Watson Health; 2022.→ (Solubility, storage conditions, adverse effects)
15. Komoroski B, et al.Dapagliflozin, a novel selective SGLT2 inhibitor, improves glycemic control in patients with type 2 diabetes mellitus.Clin Pharmacol Ther. 2009;85(5):513-519.
16. McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2019;381:1995-2008.
17. Johns TE, Lopez LM. Bisoprolol: is this just another beta-blocker for hypertension or angina? Ann Pharmacother. 1995 Apr;29(4):403-14.
18. Galougahi KK, Liu CC, Bundgaard H, Rasmussen HH. β-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. Trends Cardiovasc Med. 2012 May;22(4):83-7.
19. Kamp TJ, Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res. 2000 Dec 08;87(12):1095-102.
20. Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010;59:1-30.
21. Rekhaaiyak MR. Dapagliflozin – Leading Novel Agent in a New Class of Oral Antidiabetic Agents for Type 2 DM.Int J Res Pharm Biomed Sci. 2013;4(2):526-530.
22. Product Information. Forxiga oral tablets (dapagliflozin).Bristol-Myers Squibb Australia Pty Ltd., Victoria, Australia; 2013.
23. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control over 2 weeks in patients with Type 2 Diabetes Mellitus.Clin Pharmacol Ther. 2009;85(5):513-519.
24. Van den Heuvel L, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2).Hum Genet. 2002;111(6):544-551.
25. Leopold G, Ungethum W, Pabst J, Simane Z, Buhring KU, Wiemann H.Pharmacodynamic profile of bisoprolol, a new beta-1 selective adrenoceptor antagonist. Br J Clin Pharmacol. 1986 Sep;22(3):293-300.
26. Ventilatory effects of beta-1-receptor selective blockade with bisoprolol and metoprolol in asthmatic patients.Eur J Clin Pharmacol. 1982;23(3):203-208.
27. Product Information.Farxiga oral tablets (dapagliflozin).Bristol-Myers Squibb Company (per manufacturer), Princeton, NJ; 2022.
28. Ishida K, Horie A, Nishimura M, Taguchi M, Fujii N, Nozawa T, Inoue H, Hashimoto Y. Variability of bioavailability and intestinal absorption characteristics of bisoprolol. Drug Metab Pharmacokinet. 2013;28(6):491-6.
29. Chan SW, Chu TTW, Ho CS, Kong APS, Tomlinson B, Zeng W. Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients. Front Med (Lausanne). 2021;8:683498.
30. Ågesen FN, Weeke PE, Tfelt-Hansen P, Tfelt-Hansen J., for ESCAPE?NET. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect. 2019 Aug;7(4):e00496.
31. Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin. 2012 Nov;33(11):1359-71. [PMC free article] [PubMed]
32. Abeel M, Gupta A, Constance C. Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies. Adv Ther. 2022 Jan;39(1):391-404.
33. Product Information. Farxiga oral tablets (dapagliflozin).Bristol-Myers Squibb Company (per manufacturer), Princeton, NJ; 2022.
34. FDA briefing document. Endocrinologic and Metabolic Drugs Advisory Committee. Available from:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pdf
35. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019;381:1995–2008.
36. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM, 2015;373:2117–2128.
37. Packer M et al. Effect of SGLT2 Inhibitors on Heart Failure Outcomes. Circulation, 2020;142:1028–1039.
38. Poole-Wilson PA et al. Comparison of Bisoprolol and Placebo in Chronic Heart Failure (CIBIS-II). Lancet, 1999;353:9–13.
39. Bangalore S et al. β-Blockers and Cardiovascular Outcomes in Hypertension. Journal of the American College of Cardiology, 2017;69:2719–2731..
40. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of bisoprolol and placebo in patients with chronic heart failure (CIBIS-II). Lancet. 1999;353(9146):9–13.
41. Bangalore S, Parkar S, Messerli FH.Long-term β-blocker therapy and clinical outcomes in hypertensive patients.Journal of the American College of Cardiology. 2017;69(22):2719–2731.
42. McMurray JJV, Solomon SD, Inzucchi SE, et al.Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF).New England Journal of Medicine. 2019;381(21):1995–2008.
43. Wiviott SD, Raz I, Bonaca MP, et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58). New England Journal of Medicine. 2019;380(4):347–357.
44. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with SGLT2 inhibitors in heart failure.Circulation. 2020;142(11):1028–103
45. Handler J. Adverse effects using combined rate-slowing antihypertensive agents. J Clin Hypertens (Greenwich). 2011 Jul;13(7):529-32.
46. Saedder EA, Thomsen AH, Hasselstrøm JB, Jornil JR. Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review. Clin Case Rep. 2019 Nov;7(11):2042-2048
47. Liu W, Yan T, Chen K, Yang L, Benet LZ, Zhai S. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. Pharmacotherapy. 2020 Apr;40(4):274-290.
48. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc. 2009 Nov;57(11):1997-2003.
49. European Society of Cardiology (ESC).2023 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.European Heart Journal. 2023.
50. Ranjan, R., & Sharma, A. (2023). Optimizing cardiovascular outcomes with bisoprolol: An evidence-based perspective. Cardiovascular Therapeutics Review.